Preclinical studies and transcriptome analysis in a model of Parkinson's disease with dopaminergic ZNF746 expression
Citations

WEB OF SCIENCE

9
Citations

SCOPUS

9

초록

BackgroundThe parkin-interacting substrate (PARIS, also known as ZNF746) is a transcriptional repressor, whose accumulation and phosphorylation play central pathological roles in Parkinson's disease (PD). PARIS-induced transcriptional repression of PGC-1 alpha or MDM4 contributes to mitochondrial dysfunction and p53-dependent neuron loss in PD. Despite the important role of PARIS in PD pathogenesis, unbiased transcriptomic profiles influenced by PARIS accumulation in dopaminergic neurons remain unexplored.MethodsWe engineered Tet-Off conditional transgenic mice expressing PARIS in dopaminergic neurons, driven by DAT-PF-tTA driver mice. The conditional PARIS transgenic mice were characterized by PD-associated pathologies, including progressive dopamine cell loss, neuroinflammation, PGC-1 alpha repression, and mitochondrial proteome alteration. Motor impairment was assessed using pole and rotarod tests. L-DOPA and c-Abl inhibitors were administered to PARIS transgenic mice to evaluate their therapeutic efficacy. The transcriptomic profiles and gene ontology clusters were analyzed by bulk and single-nucleus RNA-seq for the ventral midbrains from PARIS transgenic and age-matched controls.ResultsConditional dopaminergic PARIS expression in mice led to the robust and selective dopaminergic neuron degeneration, neuroinflammation, and striatal dopamine deficits, resulting in L-DOPA-responsive motor impairments. Consistent with the results of previous reports, PARIS suppressed dopaminergic PGC-1 alpha expression, disturbed mitochondrial marker protein expression, and reduced COXIV-labeled mitochondria in dopamine neurons. Pharmacological inhibition of c-Abl activity in PARIS transgenic mice largely prevents PD-associated pathological features. Unbiased transcriptomic analysis revealed PARIS-regulated differentially expressed genes (DEGs), both collectively and in a cell-type-specific manner, along with enriched biological pathways linked to PD pathogenesis. Single-cell resolution transcriptomic analysis confirmed repression of PGC-1 alpha and several mitochondria-related target genes in dopaminergic cells. Additionally, we identified distinct glial cell subpopulations and DEGs associated with PD pathogenesis.ConclusionsConditional PARIS transgenic mice recapitulate robust and dopaminergic neuron-selective pathological features of PD, allowing the preclinical evaluation of antisymptomatic and disease-modifying therapeutic strategies within a couple of months. Based on this new PD mouse model, we provide unbiased bulk and single-nucleus transcriptomic profiles that are regulated by PARIS and potentially contribute to PD pathogenesis. A PD mouse model with flexible pathology induction capacity and a whole transcriptome could serve as a useful resource for translational PD research.

키워드

Parkinson's diseasePARISConditional transgenic modelC-AblVentral midbrain transcriptomeC-ABLALPHA-SYNUCLEINBILE-ACIDSACTIVATIONPARISPHOSPHORYLATIONUBIQUITINATIONCONTRIBUTESPGC-1-ALPHAMECHANISMS
제목
Preclinical studies and transcriptome analysis in a model of Parkinson's disease with dopaminergic ZNF746 expression
저자
Kim, Ji HunYang, SuminKim, HyojungVo, Dang-KhoaMaeng, Han-JooJo, AreumShin, Joo-HeonShin, Joo-HoBaek, Hyeon-ManLee, Gum HwaKim, Sung-HyunLim, Key-HwanDawson, Valina L.Dawson, Ted M.Joo, Jae-YeolLee, Yunjong
DOI
10.1186/s13024-025-00814-3
발행일
2025-02
유형
Article
저널명
Molecular Neurodegeneration
20
1